Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Voss

Showing results (31-40 of 49) with videos related to

Pageof 5
Sort By:
Vaccine|August 15, 2006
Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02AV Ann Stewart, Shannon M McGrath, Douglas S Walsh, et al.
Vaccine|April 1, 2006
Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02ADouglas S Walsh, Montip Gettayacamin, Wolfgang W Leitner, et al.
Journal of Virology|July 30, 2005
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesMing Li, Feng Gao, John R Mascola, et al.
Retrovirology|July 18, 2012
Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque modelMark Page, Richard Stebbings, Neil Berry, et al.
Vaccine|October 20, 2006
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteersPaul A Goepfert, Georgia D Tomaras, Helen Horton, et al.
Nature Medicine|March 23, 2004
A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and diseaseWilliam H H Reece, Margaret Pinder, Philip K Gothard, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 4, 2011
Induction of strong HIV-1-specific CD4+ T-cell responses using an HIV-1 gp120/NefTat vaccine adjuvanted with AS02A in antiretroviral-treated HIV-1-infected individualsMathias Lichterfeld, Rajesh T Gandhi, Rachel P Simmons, et al.
Vaccine|June 19, 2007
A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adultsKent E Kester, Denise A McKinney, Nadia Tornieporth, et al.
Vaccine|July 12, 2005
An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque modelJ Robert Putnak, Beth-Ann Coller, Gerald Voss, et al.
Vaccine|April 3, 2023
Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysisAgustín Ciapponi, Mabel Berrueta, Edward P K Parker, et al.
Pageof 5

Showing results (31-40 of 49) with videos related to

Sort By:
Pageof 5
Vaccine|August 15, 2006
Pre-clinical evaluation of new adjuvant formulations to improve the immunogenicity of the malaria vaccine RTS,S/AS02AV Ann Stewart, Shannon M McGrath, Douglas S Walsh, et al.
Vaccine|April 1, 2006
Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02ADouglas S Walsh, Montip Gettayacamin, Wolfgang W Leitner, et al.
Journal of Virology|July 30, 2005
Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodiesMing Li, Feng Gao, John R Mascola, et al.
Retrovirology|July 18, 2012
Heterologous protection elicited by candidate monomeric recombinant HIV-1 gp120 vaccine in the absence of cross neutralising antibodies in a macaque modelMark Page, Richard Stebbings, Neil Berry, et al.
Vaccine|October 20, 2006
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteersPaul A Goepfert, Georgia D Tomaras, Helen Horton, et al.
Nature Medicine|March 23, 2004
A CD4(+) T-cell immune response to a conserved epitope in the circumsporozoite protein correlates with protection from natural Plasmodium falciparum infection and diseaseWilliam H H Reece, Margaret Pinder, Philip K Gothard, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 4, 2011
Induction of strong HIV-1-specific CD4+ T-cell responses using an HIV-1 gp120/NefTat vaccine adjuvanted with AS02A in antiretroviral-treated HIV-1-infected individualsMathias Lichterfeld, Rajesh T Gandhi, Rachel P Simmons, et al.
Vaccine|June 19, 2007
A phase I/IIa safety, immunogenicity, and efficacy bridging randomized study of a two-dose regimen of liquid and lyophilized formulations of the candidate malaria vaccine RTS,S/AS02A in malaria-naïve adultsKent E Kester, Denise A McKinney, Nadia Tornieporth, et al.
Vaccine|July 12, 2005
An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque modelJ Robert Putnak, Beth-Ann Coller, Gerald Voss, et al.
Vaccine|April 3, 2023
Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysisAgustín Ciapponi, Mabel Berrueta, Edward P K Parker, et al.
Pageof 5